The BMPs expression and histomorphometric study of beta-TCP /rhBMP-2 Grafting on the rabbit cranial bone defects.
- Author:
Byung Sup LIM
1
;
Jae Yoon JEON
;
Chang Joo PARK
;
Jae Jung IM
;
Kyung Gyun HWANG
;
Kwang Sup SHIM
Author Information
1. Department of Dentistry/Oral and Maxillofacial Surgery, College of Medicine, Hanyang University, Korea. hkg@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Beta-Tricalcium phosphate;
bone graft;
Bone Morphogenic Protein;
bone substitute;
histomorphometry;
Immunohistochemistry
- MeSH:
Bone Substitutes;
Calcium Phosphates;
Humans;
Immunohistochemistry;
Osteogenesis;
Rabbits;
Skull;
Transplants
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2008;34(1):49-58
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The Purpose of the study was to investigate the bone morphogenic protein expression of rhBMP-2(recombinant human bone morphogenic protein-2) as singnaling molecule and beta-TCP(Tricalcium phosphate) as a bone substitute and carrier medium of rhBMP-2. MATERIALS AND METHODS: 16 rabbits divided into 2 group of each 8 rabbit. Two standardized bone defect, round bilateral defect was made in the cranium of the 8 rabbit of first group, and was grafted with 150~500micrometer diameter beta-TCP 0.25g in one side, which was soaked with rhBMP-2, and autogenous bone was grafted on another side as a positive control. Second group of 8 rabbit, only beta-TCP was grafted with same size and same manner. After 2, 4, 8, and 12 weeks, specimen was taken for microscopic immunohiostochemical and histomorphometric analysis. RESULT: Grafting beta-TCP with rhBMP show the early formation of the bone regenerative factor (BMP-4) and more quantity of new bone formation than only use of beta-TCP (8,12 week), even show less new bone formation than autogenous bone. CONCLUSION: The experimental study result that beta-TCP graft combination with rhBMP-2 as a delivery system is an effective with osteoinductive capacity and biodegradable properties, so that provide clinical availibility of composite use in reconstruction of bony defect.
